Cite

HARVARD Citation

    Han, S. et al. (2014). Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma. Journal of immunology research. p. . [Online]. 
  
Back to record